<DOC>
	<DOCNO>NCT00157053</DOCNO>
	<brief_summary>The purpose study evaluate whether rAHF-PFM safe effective treatment hemophilia A subject . The study consist 2 part : Part 1 pharmacokinetic safety study , Part 2 evaluation efficacy safety . The study open patient complete Baxter Study 069901 .</brief_summary>
	<brief_title>Study Pharmacokinetics , Efficacy Safety Recombinant Protein-Free Factor VIII ( rAHF-PFM ) Hemophilia A Patients - A Continuation Clinical Study 069901</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subject complete Baxter protocol 069901 Subject HIV1 seronegative , HIV1 seropositive , CD4+ lymphocyte count &gt; = 400/mm3 document within three month screen visit Subject ( legally acceptable representative , case study participant &gt; = 10 &lt; 18 year age ) inform nature study , agree provision , sign date informed consent form approve appropriate IRB/IEC Baxter The subject receive factor VIII product rAHFPFM upon completion Baxter protocol 069901 The subject develop inhibitor factor VIII , measure central laboratory , Baxter protocol 069901 . An inhibitor define Bethesda titer &gt; 1.0 , Bethesda titer &lt; 1.0 , confirmation use Nijmegen modification Bethesda assay titer &gt; 0.6 The subject schedule receive immunomodulating drug antiretroviral chemotherapy ( e.g. , ainterferon , steroid ) course study The subject identify investigator unable unwilling cooperate study procedure</criteria>
	<gender>Male</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Factor VIII Deficiency</keyword>
</DOC>